A phase I clinical trial (NCT00404339) that tested the tumor peptide-specific p53 vaccination (autologous DC loaded with wild-type p53) injected intranodally into inguinal nodes, has reported the strategy to be safe and effective, with promising clinical outcomes in 16 patients of advanced HNSCC who had received standard-of-care curative treatment [50,51]. The gene discussed is TP53; the disease is neoplasm.